報價延遲最少15分鐘:2026/06/04 21:44 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
20.99 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.78/--
|
|
企業價值
2.91B
|
| 資產負債 |
|
每股賬面淨值
-3.33
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape. |
